Evidence map›Paper›PMID 38253948›Full record

ArticleAnnals of surgical oncology2024

Double Negativity of MRI-Detected and Pathologically-Diagnosed Extramural Venous Invasion is a Favorable Prognostic Factor for Rectal Cancer.

Toshihiro Sakanaka, Hiromitsu Iwamoto, Kenji Matsuda, Yasuyuki Mitani, Yuki Nakamura, Daisuke Murakami, Norio Takemoto, Masato Tamiya, Takahiko Hyo, Ibu Matsuzaki and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 0 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 1 institution in 1 country.

Toshihiro SakanakaSecond Department of Surgery, Wakayama Medical University, Wakayama City, Wakayama, Japan.
Hiromitsu IwamotoSecond Department of Surgery, Wakayama Medical University, Wakayama City, Wakayama, Japan. hiwa@wakayama-med.ac.jp.
Kenji MatsudaSecond Department of Surgery, Wakayama Medical University, Wakayama City, Wakayama, Japan.
Yasuyuki MitaniSecond Department of Surgery, Wakayama Medical University, Wakayama City, Wakayama, Japan.
Yuki NakamuraSecond Department of Surgery, Wakayama Medical University, Wakayama City, Wakayama, Japan.
Daisuke MurakamiSecond Department of Surgery, Wakayama Medical University, Wakayama City, Wakayama, Japan.
Norio TakemotoSecond Department of Surgery, Wakayama Medical University, Wakayama City, Wakayama, Japan.
Masato TamiyaSecond Department of Surgery, Wakayama Medical University, Wakayama City, Wakayama, Japan.
Takahiko HyoSecond Department of Surgery, Wakayama Medical University, Wakayama City, Wakayama, Japan.
Ibu MatsuzakiDepartment of Human Pathology, Wakayama Medical University, Wakayama, Japan.
Yuichi KinoshitaDepartment of Human Pathology, Wakayama Medical University, Wakayama, Japan.
Hirokazu NagaiDepartment of Human Pathology, Wakayama Medical University, Wakayama, Japan.
Akira IkomaDepartment of Radiology, Wakayama Medical University, Wakayama, Japan.
Ryuta IwamotoDepartment of Human Pathology, Wakayama Medical University, Wakayama, Japan.
Yuichi TakahashiDepartment of Human Pathology, Wakayama Medical University, Wakayama, Japan.
Fumiyoshi KojimaDepartment of Human Pathology, Wakayama Medical University, Wakayama, Japan.
Shin-Ichi MurataDepartment of Human Pathology, Wakayama Medical University, Wakayama, Japan.
Tetsuro SonomuraDepartment of Radiology, Wakayama Medical University, Wakayama, Japan.
Manabu KawaiSecond Department of Surgery, Wakayama Medical University, Wakayama City, Wakayama, Japan.
Wakayama Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExtramural venous invasion (EMVI) is a prognostic factor in rectal cancer. There are two types: EMVI detected by magnetic resonance imaging (MRI) (mr-EMVI) and EMVI detected by pathology (p-EMVI). They have been separately evaluated, but they have not yet been concurrently evaluated. We therefore evaluate both mr-EMVI and p-EMVI in rectal cancer at the same time and clarify their association with prognosis. PATIENTS AND

methodsIncluded were the 186 consecutive patients who underwent complete radical resection of tumors ≤ stage III at Wakayama Medical University Hospital, Japan, between 2010 and 2018. All underwent preoperative MRI examination, and were reassessed for EMVI by a radiologist. Surgically resected specimens were then reassessed for EMVI by a pathologist. We assessed the correlation between positivity of mr-EMVI and p-EMVI and prognosis, and the clinicopathological background behind them.

resultsPatients with double negativity for mr-EMVI and p-EMVI had better prognosis than patients with mr-EMVI or p-EMVI positivity (p < 0.0001). Positivity for mr-EMVI or p-EMVI was a poor independent prognostic factor in multivariate analysis.

conclusionsCombined analysis of mr-EMVI and p-EMVI may enable prediction of postoperative prognosis of rectal cancer. Patients with double negativity of mr-EMVI and p-EMVI had better prognosis than patients with some form of positivity. Stated differently, patients with positivity of mr-EMVI, p-EMVI, or both had a poorer prognosis than those with double negativity. Postoperative adjuvant chemotherapy may improve poor prognosis. Combined evaluation of mr-EMVI and p-EMVI may be used to predict clinical outcomes and may be an effective prognostic predictor of rectal cancer.

Indexed as

Rectal NeoplasmsChemoradiotherapyHumansMagnetic Resonance ImagingNeoplasm InvasivenessPrognosisRetrospective Studiesmr-EMVIp-EMVIRectal cancer

Identifiers

PMID38253948
OpenAlexW4391091571

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.